Non-steroidal anti-inflammatory drugsBMJ 2000; 321 doi: https://doi.org/10.1136/bmj.321.7260.568 (Published 02 September 2000) Cite this as: BMJ 2000;321:568
Article was inconsistent
- Heather Ferguson, senior house officer in medicine,
- Tony C K Tham (email@example.com), consultant gastroenterologist
- Ulster Hospital, Dundonald, Belfast BT16 1RH
- Nordic Cochrane Centre, Rigshospitalet, DK2100 Copenhagen Ø, Denmark
EDITOR—Gøtzsche's review on non-steroidal anti-inflammatory drugs contains some inconsistencies that we would like to highlight.1 In the summary section on interventions Gøtzsche states that H2 blockers are likely to be beneficial in high risk patients who cannot avoid non-steroidal anti-inflammatory drugs, albeit to a lesser extent than omeprazole. This statement is misleading and contradicts the clinical evidence presented later in the review.
The author describes two randomised controlled trials comparing ranitidine with omeprazole2 and misoprostol.3 The results of these trials showed that ranitidine was inferior to both of these drugs in reducing ulcers induced by non-steroidal anti-inflammatory …